The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.

Phase 3

Pfizer